<DOC>
	<DOCNO>NCT00751881</DOCNO>
	<brief_summary>The primary objective study assess effect two dos teriflunomide , comparison placebo , frequency multiple sclerosis ( MS ) relapse participant relapse MS. Key secondary objective ass effect two dos teriflunomide , comparison placebo , disability progression . Other secondary objective : - To assess effect two dos teriflunomide comparison placebo : - Fatigue ; - Health-related quality life , measure impact participant 's health overall well . - To evaluate safety tolerability teriflunomide .</brief_summary>
	<brief_title>An Efficacy Study Teriflunomide Participants With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description>The study consist : - A core treatment period : Teriflunomide 7 mg Teriflunomide 14 mg placebo administer double-blind fashion fix common end date approximately 48 week randomization last participant . - An extension treatment period : high dose teriflunomide administer open-label fashion participant successfully complete core treatment period wish continue . The overall treatment period follow 4-week elimination follow-up period .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Relapsing multiple sclerosis , Two relapse prior 2 year one relapse prior year . Clinically relevant cardiovascular , hepatic , neurological , endocrine major systemic disease , Significantly impair bone marrow function , significant anemia , leukopenia thrombocytopenia , Pregnant nursing woman , Alcohol drug abuse , Prior concomitant use cladribine , mitoxantrone , immunosuppressant agent azathioprine , cyclophosphamide , cyclosporin , methotrexate mycophenolate , Human immunodeficiency virus ( HIV ) positive , Any know condition circumstance would prevent , investigator 's opinion , compliance completion study . The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>relapse multiple sclerosis</keyword>
</DOC>